A-Alpha Bio has developed a synthetic biology platform to aid in the development of drugs that interact with multiple targets
Pharmaceutical companies are pursuing increasingly challenging targets, which often require binding to multiple proteins or specificity between closely related proteins. Drug development currently requires iterative screening against one target at a time. This approach is slow, costly, and often ineffective at producing successful therapeutics.
A-Alpha Bio has developed a proprietary synthetic biology platform, called AlphaSeq, that enables screening against thousands of targets in a single experimental step. An all-at-once approach saves time, reduces cost, and improves success rates.
What can you do with AlphaSeq?
Discover biologics with a defined specificity profile
Screen antagonists against full interaction networks
Identify agonists with a large panel of target proteins
